



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Monalizumab

<b>Cat. No.:</b>	HY-P99032
<b>CAS No.:</b>	1228763-95-8
<b>Target:</b>	Checkpoint Kinase (Chk); IFNAR
<b>Pathway:</b>	Cell Cycle/DNA Damage; Immunology/Inflammation
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN- $\gamma$ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) <sup>[1][2]</sup> .								
<b>In Vitro</b>	Monalizumab blocks NKG2A and enhances CLL NK-cell mediated cytotoxicity against HLA-E-expressing K562 cells <sup>[3]</sup> . Monalizumab enhances the Enzalutamide (HY-70002) (10 $\mu$ M)-induced NK cell activation and killing of prostate cancer cells (LNCaP and 22Rv1) <sup>[5]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Monalizumab (50 $\mu$ g, intratumoral injections, together with 8 millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E <sup>+</sup> tumors in immunodeficient mice <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell<sup>[4]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 <math>\mu</math>g, together with 8 millions of activated NK cells</td> </tr> <tr> <td>Administration:</td> <td>intratumoral injections</td> </tr> <tr> <td>Result:</td> <td>Shows a synergistic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells.</td> </tr> </table>	Animal Model:	immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell <sup>[4]</sup>	Dosage:	50 $\mu$ g, together with 8 millions of activated NK cells	Administration:	intratumoral injections	Result:	Shows a synergistic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells.
Animal Model:	immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell <sup>[4]</sup>								
Dosage:	50 $\mu$ g, together with 8 millions of activated NK cells								
Administration:	intratumoral injections								
Result:	Shows a synergistic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells.								

### REFERENCES

- [1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. *J Immunother Cancer*. 2019 Oct 17;7(1):263.
- [2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2020 Sep 21;12(9):2691.
- [3]. McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. *Oncoimmunology*. 2016 Sep 9;5(10):e1226720.
- [4]. Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. *EMBO Mol Med*. 2023 Nov 8;15(11):e17804.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA